Autism & Depression Shared Risk and Your Genetics

Reviewed by the ExomeDNA Science Team | This page contains general information only. For personal health decisions, consult a qualified clinician.

Autism & Depression Shared Risk is a cross-diagnostic genetic trait derived from a multi-trait genome-wide association study (MTAG) combining data on autism spectrum disorder (ASD) and major depressive disorder (MDD). ExomeDNA scores this trait by aggregating common genetic variants that influence pathways shared between the two conditions — primarily synaptic organization, neurotrophin signaling, and neuronal RNA processing. Below: what that score means, the biology behind it, and practical steps informed by the research.

What is Autism & Depression Shared Risk?

Autism spectrum disorder and major depressive disorder are clinically distinct conditions with separate clinical criteria, yet they overlap more than many people realize. Epidemiological research consistently finds that autistic individuals experience depression at substantially higher rates than the general population — estimates range from 20 to 54 percent, compared with roughly 7 to 10 percent in neurotypical adults. This co-occurrence is not coincidental.

Geneticists have long suspected that a subset of common DNA variants contribute risk to both conditions simultaneously, acting on shared neurodevelopmental pathways long before either condition would conventionally be identified. To study this directly, researchers apply a technique called Multi-Trait Analysis of GWAS (MTAG), which combines summary statistics from two separate genome-wide association studies — one focused on autism, one on major depressive disorder — to identify variants whose effects are amplified when both traits are analyzed together.

This ExomeDNA trait, designated TRAIT_085576, reports your polygenic score from one such MTAG analysis. A higher score indicates that your genome carries, on average, more of the common variants linked to shared ASD+MDD pathways. It does not indicate autism, depression, or that either condition will develop. Polygenic scores for complex behavioral and mood-related traits explain only a modest fraction of overall risk, and environment, life experience, and protective factors all play substantial roles.

ASD is a neurodevelopmental difference characterized by variation in social communication and sensory processing. Many autistic people live full, rich, and meaningful lives. Depression, meanwhile, is one of the most common and most treatable conditions in medicine. Understanding genetic contributors to both — especially shared ones — supports more targeted wellness strategies.

The genetics behind Autism & Depression Shared Risk

Four genes in the authorized list for this trait illustrate the biological bridges between autism and depression.

RBFOX1 (RNA-binding Fox protein 1) is the most biologically prominent of the four. It is an RNA-binding protein expressed exclusively in neurons and skeletal muscle that recognizes a short sequence motif (UGCAUG) in the introns and untranslated regions of hundreds of pre-mRNAs. When RBFOX1 binds those motifs, it determines which exons are included in the final messenger RNA — a process called alternative splicing. The proteins produced by alternatively spliced mRNAs can differ meaningfully in function, localization, or binding partners.

Why does this matter for synapses? RBFOX1's direct targets include neurexins (synaptic organizers), SHANK proteins (postsynaptic scaffold components), and SYNGAP (a regulator of synaptic plasticity). By controlling which isoform of each of these proteins a neuron manufactures, RBFOX1 effectively shapes the molecular identity of every synapse in the brain. Copy number variants in RBFOX1 — deletions and duplications — are among the more robust rare genetic findings in autism spectrum disorder. Common variants near RBFOX1 influence its expression level, shifting the splicing landscape of synaptic genes across a broader population. In the context of depression, disrupted synaptic plasticity (including AMPA receptor trafficking and dendritic spine dynamics) is a well-documented pathophysiological mechanism; RBFOX1-regulated isoforms sit upstream of those processes.

NEGR1 (Neuronal Growth Regulator 1) is a GPI-anchored cell adhesion molecule belonging to the IgLON family. It is expressed on both excitatory and inhibitory neurons during development, where it promotes cell adhesion, neurite outgrowth, and synaptogenesis. Variants near NEGR1 have been associated with body mass index, ADHD, cognitive function, and — in the cross-diagnostic MTAG context — the autism-depression signal. NEGR1's role in shaping neural circuit architecture during sensitive developmental windows means that its variation may influence both the social-communication networks affected in ASD and the emotional-regulation circuits implicated in MDD.

SORCS3 (Sortilin-Related VPS10 Domain-Containing Receptor 3) is a neuronal endosomal receptor that participates in the intracellular sorting and secretion of brain-derived neurotrophic factor (BDNF). BDNF is the neurotrophic factor most closely associated with both neuronal survival during development and antidepressant action in adulthood. Standard antidepressant medications — including SSRIs — work in part by increasing BDNF availability in the prefrontal cortex and hippocampus. SORCS3 variants that alter receptor trafficking can change how effectively neurons secrete and respond to BDNF, with downstream consequences for neurodevelopment (relevant to ASD) and for the brain's capacity to remodel its circuitry in response to stress or treatment (relevant to MDD).

BAG5 (BAG Family Molecular Chaperone Regulator 5) modulates the Hsp70 chaperone cycle in neurons and has anti-apoptotic properties. Neuronal proteostasis — the quality control of protein folding and clearance — is increasingly recognized as relevant to both neurodevelopmental disorders and mood disorders. BAG5's presence in the shared-risk gene list reflects emerging evidence that cellular stress-response pathways intersect with the biology of ASD and MDD.

What the research says

Research base: Moderate.

The foundational study for this trait is Grove et al. (2019, PMID 30804558), published in Nature Genetics. This landmark autism GWAS meta-analysis included more than 18,000 ASD cases and 27,000 controls of European ancestry, identifying five genome-wide significant loci and several additional suggestive loci. Crucially, the study also applied MTAG to simultaneously analyze autism and several genetically correlated traits — including major depressive disorder — demonstrating that combining GWAS summary statistics across correlated phenotypes increases statistical power to detect shared loci. RBFOX1, NEGR1, SORCS3, and BAG5 each appeared in the MTAG or autism-primary analyses from this study.

Key statistics from the research:

• The ASD+MDD genetic correlation estimated from cross-trait LDSC analyses in related literature is approximately rg = 0.31–0.39, indicating substantial but not complete genetic overlap between the two conditions.
• Grove et al. (2019) reported a genome-wide significant signal at the NEGR1 locus (chromosome 1p31) in the MTAG analysis, with p-values reaching below 5 × 10^-8 after cross-trait combination.
• The RBFOX1 locus reached suggestive significance in the autism primary analysis and strengthened in cross-trait analyses, consistent with its established role in ASD rare-variant genetics.
• SORCS3 was implicated at genome-wide significance in the MTAG analysis, providing the first common-variant genetic link between neurotrophin trafficking and cross-diagnostic ASD+MDD risk.

The confidence tier for this trait is moderate. The MTAG methodology is statistically principled, but the phenotypic definitions across the component GWAS studies vary in how autism and depression are ascertained. Polygenic scores derived from MTAG analyses tend to show attenuated accuracy when applied across ancestries different from the discovery cohort, which was predominantly European. Users of non-European ancestry should interpret their score with additional caution.

How Autism & Depression Shared Risk affects you

A higher score on this trait indicates that your genome carries more of the common variants linked to shared autism-depression biological pathways. In practical terms, this means:

Your score does not tell you whether you are autistic or whether depression is present. Both conditions require clinical evaluation. What the score describes is your genetic predisposition toward the neurobiological pathways — synaptic organization, neurotrophin signaling, neuronal RNA splicing — that are relevant to both.

For people who are autistic, a higher shared-risk score contextualizes why monitoring for depression symptoms is worthwhile. Autistic individuals who develop depression often describe it as a qualitatively different experience from typical presentations — more somatic, more connected to social exhaustion and masking fatigue, and sometimes harder to recognize through standard screening tools. Knowing that the biological substrate for both conditions overlaps supports a proactive, rather than reactive, approach.

For people who are not autistic, a higher score reflects that the shared genetic pathways carry some additional load that may influence mood regulation, stress sensitivity, or responses to social difficulty — outcomes influenced by many biological and environmental factors beyond this single score.

For all users, the synaptic and neurotrophin mechanisms identified in this trait are responsive to environmental inputs, which opens practical avenues for support.

Working with your Autism & Depression Shared Risk result

1. Establish a mood-monitoring baseline. Especially for autistic individuals, depression can emerge gradually and be misattributed to sensory overload or social exhaustion. A simple weekly mood log — rating energy, motivation, and social comfort — can make patterns visible before symptoms become impairing.

2. Prioritize aerobic exercise for BDNF support. Physical exercise, particularly sustained aerobic activity (20-45 minutes, moderate intensity, most days), is among the most consistently replicated non-pharmacological activators of BDNF in the brain. Given SORCS3's role in BDNF trafficking, exercise-driven BDNF elevation may be especially relevant for this trait profile. Aim for activities that feel sustainable and enjoyable — swimming, cycling, brisk walking, or dancing all qualify.

3. Protect social connection quality, not just quantity. The NEGR1 and RBFOX1 biology implicated here relates to neural circuit organization for social function. For autistic individuals specifically, large or unfamiliar social situations can be depleting rather than restorative. The relevant goal is identifying the social contexts that feel genuinely connecting — typically smaller, lower-sensory-demand settings — and protecting time for those.

4. Consider psychotherapy specifically validated for autistic adults with depression. Standard CBT protocols may require adaptation for autistic presentations. Acceptance and Commitment Therapy (ACT) has been evaluated favorably in autistic adult populations and addresses psychological flexibility and values-based action rather than cognitive restructuring, which can fit better with autistic cognitive styles.

5. Support synaptic health through nutrition. Omega-3 fatty acids (EPA and DHA from marine sources) are well-established modifiers of neuronal membrane composition and synaptogenesis. Adequate dietary zinc, magnesium, and choline support neurotransmitter synthesis and synaptic function. None of these nutritional levers are substitutes for clinical care, but they represent evidence-informed lifestyle choices.

6. Discuss screening proactively with a clinician. If your score is elevated and a personal or family history of ASD or depression is present, a brief conversation with a primary care provider or mental health professional — framing it as preventive rather than crisis-driven — can establish a monitoring plan before symptoms become impairing.

Related traits and genes

The biological pathways covered by RBFOX1, NEGR1, SORCS3, and BAG5 connect this trait to several neighboring areas of ExomeDNA's trait catalog. Synaptic plasticity and BDNF signaling link this result to cognitive resilience and stress-response traits. The neuronal cell-adhesion biology of NEGR1 overlaps with traits related to social cognition and attention. Users who receive elevated scores here may also find relevant context in traits covering anxiety predisposition, ADHD-related attention variation, and neuroticism — all conditions with overlapping genetic architecture with both ASD and MDD.

For users interested in the gene-level detail, RBFOX1 is one of the most studied RNA-binding proteins in neuroscience, with an extensive literature connecting alternative splicing regulation to both neurodevelopmental and mood-related phenotypes. Its biology is foundational to understanding how a single gene can influence the molecular identity of synapses across the entire brain.

Frequently asked questions

Does a high score on this trait mean I am autistic or have depression? No. This polygenic score reflects the aggregate load of common genetic variants associated with shared biological pathways. It is not a clinical screening tool for autism spectrum disorder or major depressive disorder. Both conditions require clinical evaluation by qualified professionals and cannot be determined from a polygenic score.

Why are autism and depression studied together in one GWAS? The two conditions co-occur more than chance would predict, and statistical methods like MTAG can identify shared genetic signals that are too subtle to detect by studying each condition in isolation. Grove et al. (2019) found that combining autism and depression GWAS data increased statistical power to identify loci relevant to both, particularly at genes like SORCS3 and NEGR1.

What does RBFOX1 actually do in the brain? RBFOX1 is an RNA-binding protein that controls alternative splicing — the process by which a single gene produces multiple different protein isoforms depending on which segments of the messenger RNA are included. RBFOX1 targets include synaptic organizer proteins like neurexins, SHANK scaffolds, and SYNGAP. By regulating which isoforms of these proteins neurons produce, RBFOX1 shapes the molecular composition of synapses throughout the brain. Disruptions to RBFOX1 splicing affect both neurodevelopment (relevant to ASD) and synaptic plasticity (relevant to depression).

Is autism a disease or a difference? ASD is a neurodevelopmental condition characterized by variation in social communication, sensory processing, and patterns of interest and behavior. Many autistic people and advocates prefer identity-first language ("autistic person") and frame autism as a form of neurological diversity rather than a disease. ExomeDNA respects this framing. The co-occurrence of depression in autistic individuals is often linked to social exclusion, masking fatigue, and lack of appropriate support — not to autism itself.

Can lifestyle changes affect this genetic risk? Genetic variants are fixed, but the biological pathways they influence — particularly BDNF signaling and synaptic plasticity — are substantially modifiable by environment and behavior. Aerobic exercise, quality social connection, targeted therapy, and nutritional support are all evidence-informed levers for the pathways implicated in this trait. These do not change your DNA, but they can meaningfully affect how those pathways function.

Should I tell my clinician about this result? Yes, especially if a personal or family history of autism, depression, or related conditions is present. A clinician can help interpret what an elevated score means in the context of your full health picture, establish appropriate monitoring, and connect you with mental health support if indicated. This result is a starting point for conversation, not a conclusion.

References

Grove J, et al. Identification of common genetic risk variants for autism spectrum disorder. Nature Genetics. 2019;51(3):431-444. PMID: 30804558.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.